SCHEMBL23972793

SCHEMBL23972793

CC(C)(C)c1ccc(-c2cccc(CC(=O)N3CCc4nc(C5(c6cccc(Cl)c6)CC5)[nH]c(=O)c4C3)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.38
MTHFD2 P13995 7/20 0.37
CLPP Q16740 1/20 0.36
KDR P35968 1/20 0.35
MAPT P10636 1/20 0.35
FFAR2 O15552 1/20 0.34
NAMPT P43490 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
AURKA O14965 1/20 0.33
SHMT1 P34896 1/20 0.33
SHMT2 P34897 1/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
EPHX1 P07099 1/20 0.33
EPHX2 P34913 1/20 0.33
SCN5A Q14524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30284337 1.00 TRPV1 (0.38) TRPV1MTHFD2CLPPKDRMAPT
SCHEMBL23973063 0.96 TRPV1 (0.35) TRPV1MTHFD2CLPPMAPTFFAR2
SCHEMBL30284073 0.96 TRPV1 (0.35) TRPV1MTHFD2CLPPMAPTFFAR2
SCHEMBL30284392 0.95 MTHFD2 (0.37) TRPV1MTHFD2CLPPKDRMAPT
SCHEMBL23973002 0.95 MTHFD2 (0.37) TRPV1MTHFD2CLPPKDRMAPT
SCHEMBL23973447 0.93 GPR142 (0.39) TRPV1MTHFD2CLPPKDRFFAR2
SCHEMBL30283864 0.93 GPR142 (0.39) TRPV1MTHFD2CLPPKDRFFAR2
SCHEMBL23973451 0.93 TRPV1 (0.40) TRPV1MTHFD2CLPPKDRMAPT
SCHEMBL30284121 0.93 TRPV1 (0.40) TRPV1MTHFD2CLPPKDRMAPT
SCHEMBL23972801 0.92 MTHFD2 (0.41) TRPV1MTHFD2CLPPKDRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 TRPV1 2/4885MTHFD2 2762/4885CLPP 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.